IMPORTANT FACTS: The BeAT Heart Failure Study evaluates an investigational implantable device. The Study has been approved by the FDA and designated as an Expedited Access Pathway (EAP) program due to its potential as a therapy to treat a life-threatening disease with no approved alternative treatment.

Click here to see the FDA approval and EAP designation letters

For more information on the FDA EAP process go to:

See the 6 month data from the BeAT Heart Failure Study presented 9 May 2019 at HRS and 27-May-2019 at ESC-HF.